LY354740 is a potent and selective agonist for group II metabotropic glutamate (mGlu) receptors, mGlu2 and mGlu3 receptors, with anxiolytic activity in several animal models of anxiety, including the elevated plus maze (EPM) test. Here, we studied neuronal activation in mouse brain after EPM exposure in saline-and LY354740-treated mice using c-Fos immunoreactivity as a marker. The effect of LY354740 on c-Fos expression was also studied in cage control (no EPM) mice. Pretreatment with LY354740 (20 mg/kg, s.c.) produced robust anxiolytic behavior on the EPM. LY354740 administration decreased EPM-induced increases in c-Fos expression in the CA3 of the hippocampus, while having no significant effects on basal c-Fos expression in the hippocampus. LY354740 administration significantly increased c-Fos expression in specific limbic regions, including the lateral division of the central nucleus of the amygdala (CeL), lateral parabrachial nucleus, locus coeruleus, and Edinger-Westphal nucleus, whether or not animals were exposed to the EPM. Moreover, LY354740 administration per se significantly increased c-Fos expression in regions processing sensory information, including the paraventricular and lateral geniculate nucleus of the thalamus as well as the nucleus of the optic tract and superior colliculus. In particular, the suppression of fear-evoked neuronal activity in the hippocampus and drug-induced increases in neuronal activation in the CeL have been previously linked to the anxiolytic effects of clinically effective drugs such as benzodiazepines, and thus may contribute to anxiolytic actions of LY354740 in animal models and human anxiety patients.
INTRODUCTION
The excitatory neurotransmitter glutamate acts through ligand-gated ion channels and G-protein-coupled metabotropic glutamate (mGlu) receptors. Eight known subtypes of mGlu receptors can be divided into three groups (Group I: mGlu1, 5; Group II: mGlu2, 3; Group III: mGlu4, 6, 7, 8) based on their molecular structure, second messenger system, and pharmacological profile (Conn and Pin, 1997; Schoepp et al, 1999a) . Group II mGlu receptors are localized presynaptically outside the active zone of axon terminals, and also in postsynaptic neurons and glia (mGlu3 receptor) (Shigemoto et al, 1997; Tamaru et al, 2001) . Electrophysiological studies have demonstrated that the activation of presynaptic mGlu2/3 receptors negatively modulates the release of glutamate providing feedback that prevents excessive glutamate release (reviewed by Anwyl, 1999; Cartmell and Schoepp, 2000) . mGlu2/3 receptors may also function as heteroreceptors controlling the release of g-aminobutyric acid (GABA) and other neurotransmitters, including monoamines (eg dopamine) and neuropeptides (Cartmell and Schoepp, 2000) . In addition to the regulation of neurotransmitter release, activation of postsynaptic mGlu2/3 receptors can negatively modulate neuronal excitability and plasticity via intracellular mechanisms such as modulation of ion channels (eg potassium) and induction of long-term synaptic depression (Anwyl, 1999) .
Based on animal and early human data, modulation of excitatory neurotransmission via mGlu2/3 receptors is a novel approach to treat anxiety, as well as other psychiatric disorders (Schoepp, 2001; Schoepp and Marek, 2002; Schoepp et al, 2003) . (1S,2S,5R,6S)-2-aminobicyclo [3.1.0] hexane-2,6-dicarboxylic acid (LY354740) is a selective and potent agonist for mGlu2 and mGlu3 receptors (Monn et al, 1997) . It activates human cloned mGlu2 and mGlu3 receptors in non-neuronal cells with EC 50 values of 5 and 24 nM, respectively, while EC 50 values for other mGlu receptors were 36 mM (mGlu8) or higher (EC 50 4100 mM for mGlu1, 5, 4, 7) (reviewed by Schoepp et al, 1999b) . LY354740 produces anxiolytic-like effects in several animal models of anxiety, including fear-potentiated startle (Helton et al, 1998) , elevated plus maze (EPM) (Monn et al, 1997; Helton et al, 1998; Ferris et al, 2001) , conflict drinking test (Klodzinska et al, 1999) , and stress-induced hyperthermia (Spooren et al, 2002) . LY354740 is also active in an animal model of panic disorder (Shekhar and Keim, 2000) . In humans, LY354740 reduced CO 2 -induced panic anxiety (Levine et al, 2001; Schoepp et al, 2003) and produced anxiolytic effects in the fear-potentiated startle paradigm (Grillon et al, 2003) .
LY354740 binds to mGlu2/3 receptors primarily throughout the forebrain of rats (Schaffhauser et al, 1998; Wright et al, 2001; Schoepp et al, 2003) . In brain synapses such as the central nucleus of the amygdala (Neugebauer et al, 2000) , hippocampal perforant path (Kilbride et al, 1998 (Kilbride et al, , 2001 , medial prefrontal cortex (mPFC) (Marek et al, 2000) , nucleus accumbens (Robbe et al, 2002) , and substantia nigra (Bradley et al, 2000) , LY354740 has been shown to suppress evoked glutamate excitatory synaptic potentials/ currents (reviewed by Schoepp et al, 2003) . In particular, the intra-amygdalar injection of LY354740 disrupted fearpotentiated startle (Walker et al, 2002) , and intrahippocampal injection of LY354740 produced an anticonflict effect in the Vogel drinking test (Tatarczynska et al, 2001) , suggesting that these regions may be involved in the anxiolytic actions of LY354740 when it is administered systemically.
The immediate early gene c-Fos is induced in cells in vivo and in vitro by membrane depolarization (reviewed by Hughes and Dragunow, 1995) . The induction of c-Fos mRNA or protein has been widely used as a marker to map neuronal populations activated in vivo after pharmacological treatments or environmental stimuli. Exposure to EPM anxiety has been reported to moderately induce c-Fos expression in several limbic brain regions (Graeff et al, 1993; Duncan et al, 1996; Hinks et al, 1996) . Stronger and more widespread c-Fos induction is observed after more severe stressors (Stone and Zhang, 1995; Duncan et al, 1996; Chowdhury et al, 2000) . Moreover, the suppression of stress-induced c-Fos expression in the rat brain has been associated with the anxiolytic effects of benzodiazepines in the fear-conditioning model of anxiety (Beck and Fibiger, 1995) . Furthermore, benzodiazepine administration per se increases c-Fos expression in populations of neurons associated with modulation of stress/fear, including GABAergic cells of the lateral central amygdala (Hitzemann and Hitzemann, 1999) .
In order to study how systemic administration of the mGlu2/3 agonist affects neuronal excitability in the brain and to investigate brain regions that may mediate its anxiolytic activity, control mice were treated with saline or LY354740 (20 mg/kg, s.c.) and their brains were collected for c-Fos immunohistochemistry 2.5 h later. We also investigated if the behavioral effects of LY354740 on EPM are associated with changes in EPM-induced c-Fos expression. Here, mice were pretreated with saline or LY354740 (0.5 h), their behavior was briefly monitored on EPM, and brains were collected for c-Fos immunohistochemistry 2 h after EPM exposure.
EXPERIMENTAL PROCEDURES EPM Test
Male ICR:CD-1 mice (Harlan, Indianapolis, IN) were 5 weeks old at the time of testing. The EPM (HamiltonKinder, Poway, CA) was constructed from black Plexiglas based on a design validated by Lister (1987) . The maze consisted of two open arms (37.5 Â 5 Â 0.3 cm) and two closed arms (37.5 Â 5 Â 15 cm), which extended from the central platform (5 Â 5 cm). The maze was elevated 63 cm above the floor. Light beam breaks were recorded and analyzed automatically using Motor Monitor software (Hamilton-Kinder, Poway, CA). A modified zone map was used. The central area was extended to include the first 2.5 cm of each arm, thus the arm area was defined as the most distal (35 cm). An arm entry was recorded when the center of the mouse entered the distal part of the arm. This corresponds to the definition of the arm entry as all four legs on the arm (Lister, 1987) . Data were expressed as the time spent in open arms as a percent of total testing time, and as the number of open arm entries. The total amount of ambulations was used to determine the locomotor activity of tested mice.
Testing was performed between 0900 and 1200. On the test day, animals were transferred to the testing room in their home cages and allowed to acclimate for at least 1 h prior to saline or LY354740 (20 mg/kg, s.c.) injections. Immediately after injections, animals were placed in individual holding cages until tested 30 min later. A test session began by placing a mouse on the central platform facing the open arm to allow free exploration of the maze for 5 min. After testing, the mouse was returned to its holding cage and the maze was cleaned with methanol. Animals remained in the testing room until the brains were collected 2 h after EPM exposure. Control (no EPM) animals were injected with saline or LY354740 and placed in individual holding cages until they were killed 2.5 h later. The time point was based on our preliminary experiments and previous studies showing prominent c-Fos induction 2 h after pharmacological treatments or stress exposures (Graeff et al, 1993; Stone and Zhang, 1995; Duncan et al, 1996; Ryabinin et al, 1997) . Mice were anesthetized (5% isoflurane) and decapitated. Brains were rapidly removed, frozen in isopentane over dry ice, and stored at À801C until sectioning. The animal protocols were approved by Lilly Research Laboratories Animal Care and Use Committee and were in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23, revised 1996) .
c-Fos Immunohistochemistry
Coronal brain sections (14mm) were cut with a cryostat, thaw-mounted on Super Frost/Plus slides (Menzel-Glaeser, Germany), and stored at À201C. c-Fos expression was analyzed in the selected brain regions shown in Figure 1 . Slides were removed from the freezer, allowed to air-dry for 15 min, and fixed for 10 min in ice-cold 4% paraformaldehyde in phosphate-buffered saline (pH 7.4, PBS). After several washes in PBS containing 0.05% Tween 20 (PBST20), the sections were treated in 0.3% hydrogen peroxide in methanol for 15 min to block endogenous peroxidases. The sections were incubated for 20 min in blocking buffer containing 5% horse normal serum and 1% fatty acid free bovine serum albumin (BSA) in PBST20. After removal of the blocking buffer, incubation buffer (1% BSA in PBST20) containing goat polyclonal anti-c-Fos antibody (1 : 1000, SC-52G, Santa Cruz Biotechnology, Santa Cruz, CA) was applied overnight at 41C. Negative control sections were incubated without primary antibody. After washes with PBST20, slides were incubated with a biotinylated horse anti-goat IgG (1 : 200; Vector Laboratories, Burlingame, CA) in incubation buffer for 1 h followed by incubation with an avidin-horseradish peroxidase solution for 1 h (Vectastain Elite ABC, Vector). After washes in PBST20, visualization of bound peroxidase complexes was performed by incubating sections in a chromogen solution containing diaminobenzidine and nickel sulfate intensification (DAB Substrate kit, Vector) for 8 min. The reaction was stopped by PBST20. The sections were dehydrated and coverslipped with Permount (Fisher Chemicals, Fair Lawn, NJ) . No c-Fos signal was observed in negative control sections.
Quantification of c-Fos Immunoreactive Cells
The capture of microscopic images and cell count was performed blind to the treatment. Photomicrographs from anatomically matched sections were captured using a Spot RT digital color camera (Diagnostic Instruments, Sterling Heights, MI) under a light microscope (Leica DMR, Leica Microsystems, Wetzlar, Germany). Image Pro Plus digitizing software (Media Cybernetics, Silver Spring, ML) was used to set thresholds and count c-Fos positive cells. 
Statistical Analysis
The behavioral data were analyzed using Student's t-test. c-Fos data were analyzed by two-way analysis of variance (ANOVA), with po0.05 considered as being statistically significant. Post hoc analysis was performed using Tukey's Multiple Comparison Test.
RESULTS
Effect of LY354740 (20 mg/kg, s.c.) on EPM Behavior LY354740 (20 mg/kg, s.c.) administered 30 min prior to the EPM test significantly increased anxiolytic-like behavior in the outbred ICR:CD-1 strain of mice, which is consistent with previous reports using other mouse strains (Monn et al, 1997; Helton et al, 1998) . LY354740-treated mice spent significantly more time in the open arms and entered the open arms more frequently than saline-treated mice ( Figure  2a and b). LY354740 had no effect on closed arm time (Figure 2c ), and the total number of ambulations (locomotor activity) was not significantly different between saline and LY354740 treatments ( Figure 2d ).
Suppression of EPM-Induced c-Fos Expression in the Hippocampus by Systemic LY354740
Two-way ANOVA revealed a significant effect of the treatment (no EPM vs EPM) on the number of c-Fos 
Central c-Fos after anxiolytic LY354740
A-M Linden et al positive cells in the pyramidal cell layer of the hippocampal CA3 (po0.001), and the granular layer of the dentate gyrus (DG) (po0.05). The results also showed a significant effect of LY354740 administration in all three (CA3, po0.05; CA1, po0.01; and DG, po0.01) hippocampal subregions studied. In the CA3, there was also a significant interaction between these two factors (po0.05). Post hoc analysis confirmed that the number of c-Fos positive cells was significantly increased in the CA3 subregion 2 h after the EPM exposure (Figures 3a and 4b ). This EPM-induced c-Fos increase was suppressed by pretreatment with LY354740 (20 mg/kg, s.c.) back to the basal level (Figures 3a and 4d ). In the CA1 and DG, the numbers of c-Fos positive cells were significantly lower in LY354740-treated mice compared to the saline-treated and EPM-exposed groups of animals (Figures 3b and c 
c-Fos Induction in the Amygdala by Systemic LY354740
The EPM exposure had no significant effect (two-way ANOVA) on c-Fos expression in any of the amygdaloid nuclei studied ( Figure 5 ). Two-way ANOVA revealed that LY354740 (20 mg/kg, s.c.) treatment produced significant effects in the lateral division of the central nucleus of the amygdala (CeL, po0.0001), medial division of the central nucleus of the amygdala (CeM, po0.001), and basolateral nucleus of the amygdala (BLA, po0.05, Figure 5c ). Post hoc analysis confirmed that LY354740 administration significantly increased the number of c-Fos positive cells in the CeL (Figures 5a and 6c and d ). An increased number of scattered c-Fos positive cells were also found in the CeM after LY354740 administration (Figure 5b ). LY354740- (Figure 7k ). In the thalamus, the induction of c-Fos by LY354740 was found not only in the PVT but also in the dorsolateral geniculate nucleus of the thalamus (DLG, see below). A regionally restricted group of c-Fos positive cells was detected in the EW after LY354740 administration (Figure 8b ). In the LPB, c-Fos induction by LY354740 was most pronounced in the external areas, where quantitative analysis was performed (Figure 7j ). However, c-Fos levels were also increased in other areas of the LPB (data not shown). In the LC, LY354740 administration produced a pronounced increase of c-Fos immunoreactive cells as shown in Figure 9 .
c-Fos Induction in Central Visual Regions by Systemic lY354740
Two-way ANOVA revealed that LY354740 administration (20 mg/kg, s.c.) had significant effects in regions of the central visual system, including the DLG (po0.0001), nucleus of the optic tract (OT, po0.0001), and superficial gray layer of the superior colliculus (SuG, po0.0001). Post hoc analysis for each region confirmed a significant induction of c-Fos expression after LY354740 administration in all three regions in both control (no EPM) and EPMtreated mice (Figure 10 ). c-Fos induction in the superior colliculus was highly specific to the SuG compared to its other layers (Figure 11f ). No significant change was observed in the primary visual cortex layers IV-VI (VIS IV-VI; Figure 10d ). In addition to the strong induction by LY354740 in the OT (Figure 10b and 11d) , an increased number of c-Fos positive cells after LY354740 administration was observed in the other pretectal nucleus called the medial terminal nucleus of the accessory OT (data not shown). As mentioned above, LY354740 administration increased c-Fos expression in the EW (Figure 7i and 8) , an oculomotor nucleus receiving projections from the pretectal nuclei. The EW has recently been implicated in the regulation of stress/anxiety via its urocortin-containing neurons (Vaughan et al, 1995; Kozicz et al, 1998; Weninger et al, 1999 Weninger et al, , 2000 Skelton et al, 2000; Kozicz, 2003) , and was therefore grouped in the present study with the other stressrelated brain regions (Figure 7 ).
DISCUSSION
Pretreatment with LY354740 increased anxiolytic-like behaviors of mice on the EPM. This behavioral effect was accompanied by the blockade of EPM-induced c-Fos expression in the hippocampus. In several other brain regions, LY354740 administration alone increased neuronal activation. c-Fos expression was induced by LY354740 in stress-related brain regions such as the amygdala, EW, and LC, and also in the thalamic and midbrain structures that process sensory information. It has been shown that systemically administered LY354740 reaches the brain at pharmacologically relevant concentrations (see Schoepp et al, 2003) . However, we cannot rule out the possibility that , and LY354740-treated EPM-exposed (d) mice. Animal treatments are as described in Figure 3 . The dotted line delineates the CA3 area quantified in Figure 3 . Scale bar ¼ 100 mm.
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A-M Linden et al c-Fos induction in some brain regions is due to some as of yet undefined non-CNS effects of LY354740. In the present study, EPM exposure increased c-Fos expression significantly in the CA3 subregion of the hippocampus, but not in other limbic brain regions. This is in contrast to the previous reports of EPM-induced c-Fos expression in several limbic brain regions (Graeff et al, 1993; Duncan et al, 1996; Hinks et al, 1996) . These discrepancies may be due to longer EPM exposure times (15-30 min) along with control animals that were kept undisturbed in their home cages (Graeff et al, 1993; Duncan et al, 1996; Hinks et al, 1996) . In the present study, a 5-min exposure time and dim lighting conditions reduced the stressfulness of EPM exposure. In addition, the control animals (no EPM) were injected with saline and placed in a novel cage; thus c-Fos induction caused by handling, injections (s.c.), and a novel environment probably prevented significant differences in c-Fos expression from occurring between control and EPM-exposed animals.
Exposure to EPM increased c-Fos expression in the hippocampus. This is consistent with the reports of increased activity in the hippocampus after various stress/ fear stimuli (Beck and Fibiger, 1995; Stone and Zhang, 1995; Chowdhury et al, 2000) . The suppression of stress-induced neuronal activity in the hippocampus by LY354740 suggests that its anxiolytic effects may be mediated by its actions on hippocampal neurotransmission. A recent report demonstrating that the intrahippocampal administration of LY354740 produced anticonflict effect in rat Vogel drinking test (Tatarczynska et al, 2001 ) further supports the model where the reduction of stress-induced activity in the hippocampus is associated with the anxiolytic action of LY354740. It has been shown that anxiolytic doses of diazepam suppress stress-induced c-Fos expression in the DG and CA1 hippocampal regions (Beck and Fibiger, 1995) and high doses of chlordiazepoxide also decrease basal c-Fos expression in the CA1 (Hitzemann and Hitzemann, 1999) . Similarly, systemic administration of ethanol reduces not only novelty-induced but also basal c-Fos expression in the hippocampus (Ryabinin et al, 1997) . However, under the conditions of this study, LY354740 did not affect the basal c-Fos expression in the hippocampus.
Several studies demonstrate that mGlu2/3 receptor agonists, including LY354740, reduce excitatory postsynaptic potentials (EPSPs) via presynaptic mechanisms in the terminal fields of the medial perforant path in the DG midmolecular layer and CA1 stratum lacunosum moleculare (Kilbride et al, 1998 (Kilbride et al, , 2001 Kew et al, 2002) . mGlu2 receptors at mossy fiber-CA3 synapses function as the inhibitory autoreceptors that are activated only after excessive stimulation (Scanziani et al, 1997) . This may help to explain why LY354740 suppressed only EPM-induced, but not basal neuronal activity in the CA3 pyramidal cell layer. Moreover, electrophysiological recordings on hippocampal slices from mGlu2 receptor knockout mice demonstrated that mGlu2 receptors are not required for the basal synaptic transmission at the mossy fiber-CA3 synapse (Yokoi et al, 1996) . Intra-amygdaloid circuitry processes adversive information and regulates behavioral, autonomic, and neuroendocrine responses to stress/fear stimuli through the central nucleus, the main output region of the amygdala (Sun and Cassell, 1993; Davis et al, 1994; Pitkanen et al, 1997) . Here, we show that systemic administration of LY354740 increased neuronal activity in the CeL and dorsolateral BNST. This effect of LY354740 may be mediated locally or via neuronal pathways projecting to the amygdala. Local actions of LY354740 in the amygdala are supported by the study demonstrating that LY354740 can suppress excitatory postsynaptic currents in the central nucleus evoked by stimulation of the BLA (Neugebauer et al, 2000) . However, this suppressive effect of locally applied LY354740 does not help to explain why systemic LY354740 increased neuronal activity in the CeL in our study. Nevertheless, a role for local amygdaloid circuitry in the actions of LY354740 in suppressing fear-potentiated startles has recently been demonstrated following intra-amygdaloid (into the lateral amygdala) injections (Walker et al, 2002) . Alternatively, two brain regions projecting heavily to the CeL, the PVT, and LPB (Krukoff et al, 1993; Moga et al, 1995; Veinante and Freund-Mercier, 1998) were activated by systemic LY354740, suggesting a mechanism mediated via these structures. Based on neuroanatomical and electrophysiological characterization of neuronal circuitries within the central nucleus of amygdala, it has been suggested that inhibitory neurons in the CeL provide a strong and tonic inhibition over output neurons in the CeM (Sun and Cassell, 1993; Sun et al, 1994; Veinante and Freund-Mercier, 1998) . This model suggests that fear/stress alters the activity of CeL neurons leading to reduced inhibition (disinhibition) of CeM output neurons that target regions regulating stress/fear responses. Neuronal activity in the CeL is increased by several anxiolytic compounds, including benzodiazepines and ethanol (Beck and Fibiger, 1995; Salminen et al, 1996; Ryabinin et al, 1997; Hitzemann and Hitzemann, 1999) . These activated neurons in CeL (and scattered c-Fos positive neurons in CeM) have been shown to be GABAergic inhibitory neurons (Hitzemann and Hitzemann, 1999) . Thus, increased activity of GABAergic neurons in CeL induced by anxiolytic compounds could enhance the inhibitory tone and therefore restore the inhibition of the CeM output that was reduced by stress/fear. Since LY354740 produced a c-Fos induction pattern in the amygdala similar to benzodiazepines, a similar mechanism could underlie the anxiolytic actions of LY354740. Furthermore, this model of reduced inhibitory tone is supported by an observation that amphetamine-induced c-Fos expression in the inhibitory neurons of the CeL was significantly greater in the home compared to the novel environment, suggesting that the activity of GABAergic neurons is indeed suppressed by a more stressful environment (Day et al, 2001) . Further studies are needed to compare the level of c-Fos induction by LY35470 in the home vs a more aversive environment and to identify the neuronal populations activated by LY354740.
In addition to anxiolytic agents, c-Fos expression is induced in the CeL by different types of pharmacological agents, including anxiogenic compounds (Bittencourt and Sawchenko, 2000; Singewald and Sharp, 2000; Day et al, 2001) , severe stress (Chowdhury et al, 2000) , and peripheral autonomic challenges (McKitrick et al, 1992; Sagar et al, 1995) . Clearly, c-Fos induction in the CeL is not specific for anxiolytic agents. However, it is possible that different types of stimuli (eg anxiolytic and anxiogenic) could activate different neuronal populations in that region. Although the activation of the CeL may not per se mediate the actions of anxiolytic agents, it may be important in executing their actions by mediating neuroendocrine, autonomic, and behavioral responses initiated in other limbic brain regions.
Similarly, it appears that the same factors that induce c-Fos in CeL also induce c-Fos in LPB. The simultaneous activation of these two brain regions may be due to their interconnections.
The PVN is another region where various anxiogenic stimuli (Beck and Fibiger, 1995; Stone and Zhang, 1995; Bittencourt and Sawchenko, 2000) , and also anxiolytic agents such as diazepam (Salminen et al, 1996) , flesinoxan (5-HT 1A agonist; Compaan et al, 1996) and ethanol (Ryabinin et al, 1997) (see Trimarchi, 1992; Klooster et al, 1993) . Besides oculomotor functions, recent reports suggest the involvement of the EW in stress responses, anxiolytic actions of chronic benzodiazepine administration, and alcohol consumption (Skelton et al, 2000; Weninger et al, 2000; Bachtell et al, 2003; Kozicz, 2003) . The EW is the primary source of the novel corticotropin-related neuropeptide urocortin in the rat and mouse brain (Vaughan et al, 1995; Kozicz et al, 1998; Weninger et al, 1999) . The functional role of urocortin pathway and activation of EW neurons is currently under intense investigation. Our results suggest a role for the EWurocortin pathway in the anxiolytic effects of LY354740. The role of glutamate neurotransmission in the regulation of neuronal activity in the EW is supported by the observation that ionotropic glutamate receptor antagonists such as ketamine also induced c-Fos in the EW (Craner et al, 1992) .
Systemic LY354740 increased c-Fos expression in several central visual regions, including DLG, OT, and SuG. This effect is not specific for mGlu2/3 receptor agonists since systemic nicotine induces c-Fos expression in the same central visual pathways (Ren and Sagar, 1992; Salminen et al, 1996) , suggesting a similar or converging mechanism. Consistent with our results, Lam et al (1999) have reported that systemic LY354740 increased glucose utilization in the SuG. Changes in visual stimulation also induce c-Fos in the DLG, OT, and SuG, but not in the EW (Craner et al, 1992; Montero and Jian, 1995; Lu et al, 2001) . The c-Fos induction observed in the present study may be due to changes in neuronal activity in the retina or to local mGlu2 and/or mGlu3 receptor activation. Strong mGlu2/3 receptor immunoreactivity has been detected in the optic layer of the superior colliculus and also in the retina (Koulen et al, 1996; Cai and Pourcho, 1999; Kim and Jeon, 1999) . In addition, a high level of LY354740 binding has been detected in the superior colliculus (Wright et al, 2001) . Local effect in the SuG is supported by the electrophysiological studies showing that applications of group II mGlu receptor agonists and antagonists on neurons located in the SuG modulate responses to visual stimuli (Cirone and Salt, 2001 ). Finally, increased activity of thalamic and midbrain regions processing sensory information may be linked to the effects of LY354740 on the arousal or alertness of the animal. For example, the DLG receives inputs from the CeA and LC (DeLima and Singer, 1987; Cain et al, 2002) , both of which were activated by LY354740 in the present study. Overall, the functional significance of these changes in sensory and visual brain structures following LY354740 requires further investigation. It is possible that the activation of visual pathways by systemic LY354740 could produce increased c-Fos expression levels in stress-sensitive brain regions. In addition, the effects of LY354740 on the visual pathways could also affect the EPM behavior, given the importance of visual cues in this test. However, LY354740 is active in several other anxiety tests that are not dependent on visual cues, for example, stress-induced hyperthermia (Spooren et al, 2002) and conflict drinking test (Klodzinska et al, 1999) . Moreover, LY354740 administered locally to the hippocampus or amygdala produces anxiolytic-like behaviors (Tatarczynska et al, 2001; Walker et al, 2002) , suggesting that the activation of visual regions by systemic LY354740 is most likely unrelated to its anxiolytic actions.
In summary, our results show that the anxiolytic activity of LY354740 on the EPM was associated with the reduction of EPM-induced c-Fos expression in the hippocampus. Interestingly, like clinically effective anxiolytics such as benzodiazepines, LY354740 induced c-Fos expression in various other stress-sensitive regions of the brain such as the lateral portion of the central nucleus of the amygdala. These results support an important role of mGlu2/3 receptors in the modulation of neuronal excitability in stress/fear pathways, and further implicate mGlu receptors as novel targets to treat anxiety disorders. . Animal treatments are as described in Figure 3 . Scale bar ¼ 100 mm. Op, optic layer of the superior colliculus; Zo, zonal layer of the superior colliculus.
